Protalix BioTherapeutics Inc. (DE) Common Stock (PLX)

FairStock Score: 27/100 — RISKY

Key Financials

Strengths

• Generates $7 million in annual free cash flow (4.0% yield on market cap)
• High return on equity of 27.3% demonstrating efficient capital deployment
• Conservative balance sheet with debt-to-equity of just 0.13, providing financial flexibility

Concerns

• Currently unprofitable—sustained losses could lead to dilutive capital raises or balance sheet deterioration
• Revenue declining at 49.9% year-over-year signals potential demand weakness or market share loss
• Weak Piotroski F-Score of 2/9 suggests deteriorating financial quality across multiple dimensions
• Altman Z-Score of -3.0 places it in the financial distress zone—elevated bankruptcy risk

AI Analysis

Protalix BioTherapeutics Inc. (DE) Common Stock is a micro-cap healthcare company valued at $170 million. Revenue stands at $76 million, though the company is currently unprofitable. From a quality standpoint, Protalix shows weak Piotroski F-Score of 2/9 signaling deteriorating fundamentals and distressed Altman Z-Score of -3.0 warrants caution. On valuation, the stock is attractively valued at 10.5x earnings, with trades above its Graham Number with a negative 32% margin. Growth dynamics show revenue growing at -49.9% and profit growth of -184.8%. Our composite FairStock Score of 27/100 reflects below-average fundamentals overall. This combination of reasonable valuation, solid returns, and conservative leverage makes it worth a closer look for value-oriented portfolios.

Bull Case

The market underappreciates Protalix's consistent 27% ROE at just 11x earnings—a re-rating toward sector peers could unlock 30-50% upside. With $7 million in annual free cash flow (4.0% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Without a clear path to profitability, continued cash burn forces either dilutive equity raises or debt accumulation that destroys shareholder value. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer